# OnCo record paper-imerge-imetelstat-mds-lancet-2024 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-imerge-imetelstat-mds-lancet-2024/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-imerge-imetelstat-mds-lancet-2024" ;
  schema:name "IMerge: imetelstat, a telomerase inhibitor, for transfusion-dependent lower-risk MDS after erythropoietin has failed"@en ;
  schema:description "In IMerge, imetelstat, the first telomerase inhibitor to reach approval, freed about 40% of heavily transfused MDS patients from transfusions for eight weeks and 28% for six months, versus 15% and 3% with placebo."@en ;
  schema:url <https://onco.cc/key-papers/paper-imerge-imetelstat-mds-lancet-2024/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://pubmed.ncbi.nlm.nih.gov/?term=IMerge%20imetelstat%20lower-risk%20MDS%20Platzbecker%20Lancet%202024>, <https://clinicaltrials.gov/study/NCT02598661> ;
  schema:sameAs <https://doi.org/10.1016/S0140-6736(23)01724-5> ;
  schema:datePublished "2024"^^xsd:gYear ;
  schema:author "Platzbecker U, Santini V, Fenaux P, et al." ;
  onco:related <https://onco.cc/key-papers/paper-commands-luspatercept-mds-lancet-2023/> ;
  onco:cancers <https://onco.cc/cancers/mds/> ;
  onco:drugs <https://onco.cc/drugs/imetelstat/>, <https://onco.cc/drugs/luspatercept/> ;
  onco:terms <https://onco.cc/terms/orr/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-undruggable-targets/>, <https://onco.cc/bottlenecks/b-toxicity-qol/> ;
  onco:journals <https://onco.cc/journals/lancet/> .